If you’ve ever run a clean experiment on paper but ended up with messy, confusing results, you’re not alone. One of the most common frustrations researchers face is unexpected bands or signals caused by polyclonal antibody binding to off-target proteins. It’s especially tricky because polyclonal antibodies are widely used for their sensitivity, yet that same strength can quickly turn into a drawback. [Read more…]
Fiocruz and Caring Cross To Offer Drastically More Affordable CAR-T Therapy in Brazil and Latin America
Local production will permit CAR-T treatment to be available free of charge to patients.
The cost to the Brazilian public health system will be slashed to 10% of the amount currently charged in Europe and the USA (only US$35,000 per dose).
RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 — Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government’s Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection. [Read more…]
PeptiGrowth Inc. is launching a Novel Synthetic Peptide TPO-alternative peptide (TPOR agonist)
March 26, 2024, Chiyoda-ku, Tokyo – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “TPO alternative peptide (TPOR agonist)” which has equivalent function to recombinant TPO (Thrombopoietin). This product will be on the market at the end of March 2024. [Read more…]
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies
The Woodlands, TX, and St. Louis, MO, March 14, 2024 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies. [Read more…]
Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia
Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer Patients
SEATTLE, WA, March 19, 2024 – Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT)designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukemia (AML). [Read more…]
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 62
- Next Page »